Cardiovascular risk associated with celecoxib or etoricoxib: A meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen

Minerva Cardioangiologica

Volumn 62, Issue 6, 2014, Pages 437-448

  De Vecchis, R ^a   Baldi, C ^b   Di Biase, G ^c   Ariano, C ^a   Cioppa, C ^a   Giasi, A ^a   Valente, L ^d   Cantatrione, S ^a  

^a Cardiology Unit   (Italy)

^b UNIVERSITY HOSPITAL SAN GIOVANNI DI DIO E RUGGI D ARAGONA   (Italy)

^c Neurorehabilitation Unit Clinica S Maria del Pozzo   (Italy)

^d Orthopedic Outpatient Unit   (Italy)

Author keywords

Cardiovascular diseases; Celecoxib; Drug safety; Etoricoxib; Meta analysis

Indexed keywords

CELECOXIB; ETORICOXIB; NAPROXEN; PLACEBO; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; SULFONAMIDE; SULFONE;

ACUTE HEART INFARCTION; ADVERSE OUTCOME; ANKYLOSING SPONDYLITIS; ARTICLE; BACKACHE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; META ANALYSIS; OSTEOARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; COMPARATIVE STUDY; RISK; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; NAPROXEN; PYRAZOLES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; RISK FACTORS; SULFONAMIDES; SULFONES;

EID: 84926160213     PISSN: 00264725     EISSN: 18271618     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert ICA; American Heart Association. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 2007;115:1634-42.
2. Vardeny O, Solomon SD. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk. Cardiol Clin 2008;26:589-601.
3. Patrono C, Baigent C Nonsteroidal anti-inflammatory drugs and the heart. Circulation 2014;129:907-16.
4. Bombardier C. An evidence-based evaluation of the gastrointestinal safety of coxibs. Am J Cardiol 2002;89:3D-9D.
5. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K et al. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.
6. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-91.
7. Brooks J, Warburton R, Beales IL. Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidance. Ther Adv Chronic Dis 2013;4:206-22.
8. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J et al.; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 2012;64:465-74.
9. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
10. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
11. Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS et al. Gastrointestinal tolera-bility and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003;139:539-46.
12. Patrono C, Rocca B. Nonsteroidal antiinflammatory drugs: past, present and future. Pharmacol Res 2009;59:285-9.
13. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxy-genase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41:1591-602.
14. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999;74:1095-105.
15. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999;282:1921-8.
16. Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM et al. Reduced incidence of gas-troduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001;96:1019-27.
17. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≤65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63.
18. Matsumoto AK, Melian A, Mandel DR, Mcllwain HH, Borenstein D, Zhao PL et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623-30.
19. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
20. Kivitz AJ, Moskowitz RW, Woods E, Hubbard RC, Verburg KM, Lefkowith JB et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001;29:467-79.
21. Williams GW, Hubbard RC, Yu SS, Zhao W, Geis GS. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001;23:213-27.
22. McKenna F, Borenstein D, Wendt H, Wallemark C, Lefkowith JB, Geis GS. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001;30:11-8.
23. Pincus T, Koch G, Lei H, Mangal B, Sokka T, Moskowitz R et al. Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 2004;63:931-9.
24. Birbara CA, Puopolo AD, Munoz DR, Sheldon EA, Mangione A, Bohidar NR et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-ox-ygenase-2 selective inhibitor: improvement in pain and disability-a randomized, placebo-controlled, 3-month trial. J Pain 2003;4:307-15.
25. Palmer R, Weiss R, Zusman RM, Haig A, Flavin S, MacDonald B. Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors. Am J Hypertens 2003;16:135-9.
26. Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cy-clooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002;50:857-60.
27. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.
28. Ta LE, Dionne RA. Treatment of painful temporomandibular joints with a cyclooxygenase-2 inhibitor: a randomized placebo-controlled comparison of celecoxib to naproxen. Pain 2004;111:13-21.
29. Dougados M, Behier JM, Jolchine I, Calin A, Van Der Heijde D, Olivieri I et al. Efficacy of celecoxib, a cy-clooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 2001;44:180-5.
30. Di Battiste PM, Chen C, Viscusi J, Curtis SP, Cannon CP. Etoricoxib has no adverse effects on biomarkers of cardiovascular risk in patients with osteoarthritis. J Am Coll Cardiol 2004;43:511A.
31. Curtis SP, Losada B, Bosi-Ferraz M, Saenz R, Miller ER, Ray P et al. Etoricoxib and diclofenac demonstrate similar efficacy in a 174-week randomized study of rheumatoid arthritis patients. Arthritis Rheum 2003;48(9, Suppl.):S124-S5.
32. Matsumoto AK, Melian A, Mandel DR, Mcllwain HH, Borenstein D, Zhao PL et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623-30.
33. Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract 2002;3:10.
34. Hunt RH, Harper S, Callegari P, Yu C, Quan H, Evans J et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-10.
35. Tsoukas C, Eyster E, Mukhpadhyay S, Giallells K. Efficacy of etoricoxib in the treatment of hemophilic arthropathy. Arthritis Rheum 2001;44:S124-S124.
36. Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002;41:1052-61.
37. Reginster JY, Fischer CL, Beaulieu A, Malmstrom K, Curtis SP, Miller ER et al. Etoricoxib demonstrates similar efficacy and improved gastrointestinal safety compared to naproxen in two 138-week randomized studies of osteoarthritis patients. Ann Rheum Dis 2004;63
38. Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49-58.
39. Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol 2003;98:1725-33.
40. Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT, Wittmer BA et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005;80:470-9.
41. Van Der Heijde D, Baraf HS, Ramos-Remus C, Calin A, "weaver AL, Schiff M et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005;52:1205-15.
42. Pallay RM, Seger W, Adler JL, Ettlinger RE, Quaidoo EA, Lipetz R et al. Etoricoxib reduced pain and disability and improved quality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. Scand J Rheumatol 2004;33:257-66.
43. Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-8.
44. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-55.
45. Gibofsky A, Williams GW, McKenna F, Fort JG. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum 2003;48:3102-11.
46. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. Journal of American Medical Association 2002;287:64-71.
47. Pfizer, Inc. Protocol N49-96-02-023: A double-blind, placebo controlled, randomized comparison study of the efficacy and safety of SC-58635 100mg, 200 mg and 400 mg BID and naproxen 500 mg BID in treating the signs and symptoms of rheumatoid arthritis; 1998. [cited 2014 October 8]. Available from: http://www.clinicalstudyresults.org/documents/company-study-79-19.pdf
48. Pfizer, Inc. Protocol N49-96-02-060: A multicenter, doubleblind, placebo controlled comparison study of the efficacy of SC-58635 200 mg QD versus SC-58635 100mg BID in treating the signs and symptoms of osteoarthritis of the knee; 1998. [cited 2014 October 8]. Available from: http://www.clinicalstudyresults.org/documents/companystudy-79-l4.pdf
49. ™ (Etoricoxib Tablets), [cited 2014 October 8]. Available from: 2005; http://origin. www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B2-01-Mer-ck-Etoricoxib.pdf
50. Pfizer, Inc. Protocol N49-97-02-071: A multicenter, doubleblind, parallel group study comparing the incidence of gastroduodenal ulcer associated with SC-58635 200mg BID with that of diclofenac 75 mg BID and ibuprofen 800mg TID, taken for 12 weeks in patients with osteoarthritis or rheumatoid arthritis; 1998. [cited 2014 October 8]. Available from: http://www.clinicalstudyresults.org/documents/companys-tudy-79-4.pdf
51. Levin B. Celecoxib in adenoma prevention - the PreSAP Trial. Slide presentation at: Meeting of the FDA Advisory Committee on COX-2 Inhibitors and NSAIDS; February 16-18, 2005; Gaithersburg, MD, USA. [cited 2014 October 8]. Available from: http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4090S1-09-FDA-Levin. ppt